I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Hyperlactatemia is common after cardiac surgery. Impaired tissue oxygenation leads to increased anaerobic metabolism and production of pyruvate, which is subsequently converted to lactate. Numerous studies have established the use of serum lactate concentration as a marker of global tissue hypoxia in circulatory shock, but after cardiac surgery hyperlactatemia may occur as a result of other mechanisms, such as the stress response to surgery and the use of β-adrenergic,\[[@ref1][@ref2]\] and other diseases also have reported, such as sepsis.\[[@ref3][@ref4]\] Therefore, after cardiac surgery, hyperlactatemia may not be a reliable means of judging the adequacy of tissue oxygenation.

A normal central venous oxygen saturation (ScvO~2~) generally indicates that oxygen delivery (DO~2~) is sufficient to meet oxygen consumption (VO~2~), and further increasing DO~2~ is not necessary. A persistently normal ScvO~2~ and decreasing serum lactate concentration normally reflects a resolving oxygen deficit, and that any oxygen debt is being repaid. Nevertheless, ScvO~2~ may not reflect tissue hypoxia when VO~2~ is impaired by mitochondrial dysfunction or cytopathic hypoxia,\[[@ref5]\] or when microcirculatory failure results in shunting of blood away from metabolically active but hypoxic tissues.\[[@ref6]\] Therefore, neither ScvO~2~ nor serum lactate concentration can be completely relied upon to detect clinically important anaerobic metabolism. It may not be clear how to manage cardiac surgical patients with a normal ScvO~2~ and hyperlactatemia, and the inappropriate use of excessive volume expansion or positive inotropic agents carries substantial risks.

It is important, therefore, to find reliable indices to predict when an increase in DO~2~ will reduce the oxygen debt, reflected by an increase in VO~2~. A recent study showed that the ratio between veno-arterial carbon dioxide difference and arterial-venous oxygen difference (P(v−a)CO~2~/C(a−v)O~2~) is a hallmark of oxygen deficit caused by acute circulatory failure.\[[@ref7]\]

As oxygen supply dependency, reflected by derangements in the relationship between VO~2~ and DO~2~, is a hallmark of acute circulatory failure.\[[@ref8]\] We hypothesized that P(v−a) CO~2~/C(a−v)O~2~ can be used as an index of global tissue hypoxia in cardiac surgery patients. We undertook serial measurements of VO~2~ because DO~2~ changed after cardiac surgery to illuminate the relationship between the two parameters.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

We prospectively collected the data of a cohort of consecutive adults who underwent cardiac surgery between January 2012 and August 2014 at the Peking Union Medical College Hospital (PUMCH), and were admitted to the 15-bed general Intensive Care Unit (ICU) for postoperative care. The Institutional Research and Ethics Committee of the PUMCH approved this study for human subjects. Because the laboratory tests undertaken and the data collected were part of routine clinical practice, the study was observational and thus informed consent was not required.

Patients {#sec2-1}
--------

We collected data from patients with hyperlactatemia and normal ScvO~2~, and in whom changes in therapy during the first 6 h of postoperative care resulted in changes in DO~2~. During the study period, 290 patients after cardiac surgery were admitted to the ICU and received pulse contour continuous cardiac output (PiCCO) monitoring (PiCCO; Pulsion Medical Systems, Munich, Germany). Indications for PiCCO catheterization were: Left ventricular ejection fraction \<45%; history of myocardial infarction; resection of a ventricular aneurysm; repeat coronary artery bypass grafting; left main or complex coronary artery disease; replacement of two valves; and hemodynamic instability. Two hundred and twenty-one were found to have hyperlactatemia and normal ScvO~2~. Inclusion criteria were: A serum lactate concentration \>2 mmol/L; ScvO~2~ \>60.8% on admission to the ICU (considered the normal ScvO~2~ for cardiac surgical patients);\[[@ref9]\] and resuscitation that resulted in changes in DO~2~ of \>10%.\[[@ref8]\]

The interventions made to improve the DO~2~ were chosen at the discretion and clinical judgment of the attending physicians. Of the 221 patients, interventions were made to improve DO~2~ in 123; the remaining 98 were managed supportively and observed for improvement in serum lactate concentration. Of those patients in whom an intervention was made, an improvement of DO~2~ ≥10% was only seen in 72 (58.5%). A patient flow chart is shown in [Figure 1](#F1){ref-type="fig"}.

![Study flow chart. PiCCO: Pulse contour continuous cardiac output; ScvO~2~: Central venous oxygen saturation; DO~2~: Oxygen delivery.](CMJ-128-1306-g001){#F1}

Measurements {#sec2-2}
------------

Arterial pressure and heart rate were monitored continuously using a femoral artery catheter and the PiCCO plus device (Pulsion Medical Systems, Munich, Germany). Clinical strategies to improve DO~2~ included intravenous fluid challenges and the use of positive inotropic agents. If the stroke volume variation (SVV) (measured in patients in sinus rhythm who were mechanically ventilated and fully adapted to the ventilator settings) exceeded 13%, a fluid challenge was given until the SVV fell below 13%. Thereafter, if the cardiac index (*CI*) was \<2.5 L·min^−1^·m^−2^, dobutamine, milrinone or epinephrine was administered as an intravenous infusion to achieve a *CI* \>2.5 L·min^−1^·m^−2^. The doses of inotropes were moderated in the presence of cardiac arrhythmia. If there was severe hypotension (systolic blood pressure ≤60 mmHg), norepinephrine was administered as an intravenous infusion, but the dose titrated so that the systemic vascular resistance index (SVRI) did not exceed 2500 dyn·s^-1^·cm^-5^·m^-2^. After each intervention, *CI*, stroke volume index, global end-diastolic volume index (GEDVI), and SVRI were measured using a transpulmonary thermodilution technique with the mean cardiac output (CO) of three measurements within 10% of each other used to calculate each variable. All measurements were undertaken in a stable environment in the absence of any other intervention likely to alter oxygen demand or delivery, such as changes in sedation, physiotherapy, and tracheobronchial toilet. Arterial and central venous blood samples were taken for measurement of acid-base status (Abl 3 Automated Blood Gas Analyzer, Radiometer, Copenhagen, Denmark), hemoglobin (Hb) concentration, and oxygen saturation (Hemoximeter, OSM 3, Radiometer, Copenhagen, Denmark). Arterial lactate concentrations were determined enzymatically (Hitachi Analyzer, Tokyo, Japan). The normal blood lactate value for our laboratory was \<2.0 mmol/L. Oxygen-derived variables were calculated using standard formulae. Veno-arterial carbon dioxide difference (P(v−a)CO~2~) and the ratio of P(v−a)CO~2~/C(a−v)O~2~ were calculated using the following formulae:

P(v−a)CO~2~ = PvCO~2~ − PaCO~2~.

Ratio = P(v−a)CO~2~/(CaO~2~ −CvO~2~).

The anion gap (AG) was calculated as follows:

AG = (\[Na^+^\] + \[K^+^\]) − (\[Cl^−^\] + \[HCO~3~^−^\]) and corrected for the effect of abnormal albumin concentration thus: Corrected anion gap (AGcorrected) (mmol/L) = AG + 0.25× (normal albumin − observed albumin) (g/L).\[[@ref10]\]

Finally, we divided patients who responded to interventions to improve DO~2~ into two groups on the basis of the resultant change in VO~2~: In the first group, an improvement in VO~2~ was observed (∆VO~2~ \>0%, the "VO~2~ increase group"); in the second VO~2~ remained unchanged or declined (∆VO~2~ ≤0% the "VO~2~ no-increase group").

Statistical analysis {#sec2-3}
--------------------

A descriptive analysis was undertaken. All normally distributed data were expressed as the mean ± standard deviation (SD) unless otherwise specified. Differences between baseline variables and those recorded after intervention in the two groups were tested for statistical significance using the independent-samples *t*-test for continuous data and the Chi-square test for categorical variables. All comparisons were two-tailed, and *P* \< 0.05 was required to exclude the null hypothesis. We also constructed receiver operator characteristic (ROC) curves to test the ability of the P(v−a)CO~2~/C(a−v)O~2~ ratio at baseline to predict an increase in VO~2~ in patients in whom DO~2~ responded to intervention. The areas under the ROC curves (AUCs) are expressed as mean (95% confidence interval \[*CI*\]) and were compared using the Hanley--McNeil test. All statistical analyses were undertaken using the SPSS software package (version 13.0, SPSS, Chicago, IL, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Seventy-two patients admitted the ICU after cardiac surgery fulfilled the inclusion criteria \[[Figure 1](#F1){ref-type="fig"}\]. On admission, their mean baseline ScvO~2~ was 75.3% ± 6.9% and serum lactate concentration 5.6 ± 3.1 mml/L; their demographic and physiological data and outcomes are shown in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of patients after cardiac surgery

  Characteristics                                       Values
  ----------------------------------------------------- ------------------
  Age (mean ± SD), years                                54 ± 19
  Sex (male/female), *n*                                42/30
  Body mass index (mean ± SD), kg/m^2^                  23.5 ± 3.0
  APACHE II score (mean ± SD)                           19.6 ± 8.6
  Type of surgery, *n*                                  
   Coronary artery bypass graft                         27
   Valve replacement                                    33
    Aortic                                              18
    Mitral                                              12
    Aortic + mitral                                     3
   Pulmonary endarterectomy                             4
   Resection of cardiac tumor                           6
   Fontan procedure                                     2
  Preoperative ejection fraction, %                     58.3 ± 14.9
  Preoperative creatinine, μmol/L                       59.5 (53.5-98.8)
  History, *n* (%)                                      
   Previous myocardial infarction                       18 (25)
   Hypertension                                         33 (45.8)
   Diabetes                                             30 (41.7)
   Cerebrovascular disease                              15 (20.8)
   Peripheral vascular disease                          3 (4.2)
  Emergency surgery, *n* (%)                            48 (66.7)
  Preoperative cardiac shock, *n* (%)                   3 (4.2)
  Use of IABP preoperatively, *n* (%)                   3 (4.2)
  Use of IABP surgery, *n* (%)                          15 (20.8)
  Use of IABP after surgery, *n* (%)                    9 (12.5)
  Patients receiving vasopressor                        
   Norepinephrine, *n* (%)                              57 (79.2)
   Norepinephrine dose (mean ± SD), μg∙kg^−1^∙min^−1^   0.39 ± 0.40
  Patients receiving inotropic agent                    
   Dobutamine, *n* (%)                                  9 (12.5)
   Dobutamine dose (mean ± SD), μg∙kg^−1^∙min^−1^       2.99 ± 2.56
   Epinephrine, *n* (%)                                 54 (75)
   Epinephrine dose (mean ± SD), μg∙kg^−1^∙min^−1^      0.24 ± 0.53
   Milrinone, *n* (%)                                   36 (50)
   Milrinone dose (mean ± SD), μg∙kg^−1^∙min^−1^        0.37 ± 0.20
  DO~2~ (mean ± SD), ml∙min^−1^∙m^−2^                   438.2 ± 138.6
  VO~2~ (mean ± SD), ml∙min^−1^∙m^−2^                   102.5 ± 35.4
  ERO~2~, %                                             24.6 ± 9.4
  ScvO~2~, %                                            75.3 ± 6.9
  Lactate (mean ± SD), mmol/L                           5.6 ± 3.1
  P(v−a)CO~2~ (mean ± SD), mmHg                         5.8 ± 2.5
  P(v−a)CO~2~/C(a−v)O~2~ ratio (mean ± SD), mmHg/ml     1.9 ± 1.1
  AGcorrected (mean ± SD), mmol/L                       18.8 ± 4.5
  Length ICU stay, days                                 8.9 ± 5.7
  Length hospital stay, days                            42.8 ± 20.9
  Mortality at day 28, %                                16.7

APACHE II: Acute physiological and chronic health evaluation II score; IABP: Intra-aortic balloon pump; DO~2~: Oxygen delivery; VO~2~: Oxygen consumption; ERO~2~: Oxygen extraction ratio; ScvO~2~: Central venous oxygen saturation; AGcorrected: Corrected anion gap; P(v-a)CO~2~: Veno-arterial carbon dioxide difference; C(a-v)O~2~: Arterial-venous oxygen difference; ICU: Intensive Care Unit; SD: Standard deviation.

Clinical management {#sec2-4}
-------------------

Improvements in DO~2~ were achieved using one or more of the following strategies: Intravenous fluid challenge (*n* = 58); dobutamine (*n* = 9), milrinone (*n* = 36) or epinephrine (*n* = 58) infusion; blood transfusion (*n* = 9); or an increase the positive end-expiratory pressure (*n* = 2). Data from the 72 patients demonstrated that changes in VO~2~ (101 ± 35 vs. 126 ± 47 ml·min^−1^·m^−2^; *P* = 0.003) paralleled changes in DO~2~ (438 ± 139 vs. 531 ± 159 ml·min^−1^·m^−2^; *P* \< 0.001). Of the patients in whom DO~2~ improved by \>10%, VO~2~ improved in 48 patients (∆VO~2~ \>0%), but not in 24 (∆VO~2~ ≤0%).

Differences between the oxygen consumption (VO~2~) increase and VO~2~ no-increase groups {#sec2-5}
----------------------------------------------------------------------------------------

There were no significant differences between the groups in terms of baseline patient characteristics, such as acute physiology and chronic health evaluation II scores, preoperative ejection fraction, and New York Heart Association functional heart failure class. There were also no differences in terms of surgery characteristics, such as cardiopulmonary bypass (CPB) time and aortic cross-clamping time. There were also no significant physiological differences between the groups, such as the lowest mean arterial pressure during CPB, the highest serum lactate concentration, the lowest base excess, the lowest serum bicarbonate concentration or the volume of blood transfused. Finally, there were no significant differences in the need for postoperative vasopressor and inotropic agents \[[Table 2](#T2){ref-type="table"}\].

###### 

Physiological and surgical characteristics of the VO~2~ increase and VO~2~ no-increase groups

  Characteristics                                            VO~2~ increase group (*n* = 48)   VO~2~ no-increase group (*n* = 24)   *P*
  ---------------------------------------------------------- --------------------------------- ------------------------------------ -------
  APACHE II scores on admission to ICU (mean ± SD)           18.6 ± 8.5                        21.4 ± 8.8                           0.460
  Preoperative left ventricular ejection fraction, %         57.5 ± 16.4                       60.1 ± 12.1                          0.706
  Preoperative NYHA heart failure class, *n*                                                                                        
   I                                                         0                                 3                                    0.502
   II                                                        15                                6                                    
   III                                                       24                                9                                    
   IV                                                        9                                 6                                    
  The percentage of accepted CPB                             100                               100                                  
  CPB time, min                                              114.4 ± 47.6                      116.4 ± 32.9                         0.916
  Aortic cross-clamp time, min                               72.8 ± 34.2                       79.5 ± 27.8                          0.634
  Lowest MAP during CPB, mmHg                                60.6 ± 12.1                       60.5 ± 8.2                           0.979
  Blood transfusion during surgery (median \[IQR\]), units   4 \[0−4\]                         4 \[2.25−5.50\]                      0.312
  Lowest lactate during CPB (mean ± SD), mmol/L              5.3 ± 3.4                         4.9 ± 2.1                            0.785
  Lowest base excess during CPB (mean ± SD), mmol/L          −4.4 ± 3.0                        −4.3 ± 2.2                           0.927
  Lowest bicarbonate during CPB (mean ± SD), mmol/L          21.3 ± 1.9                        22.0 ± 1.6                           0.4
  Postoperative ejection fraction at 2 weeks, %              57.7 ± 14.7                       61.6 ± 13.1                          0.567
  Number of patients receiving a vasopressor                                                                                        
   Norepinephrine, *n* (%)                                   39 (81.2)                         18 (75.0)                            0.722
   Norepinephrine dose (mean ± SD), μg∙kg^−1^∙min^−1^        0.39 ± 0.43                       0.37 ± 0.37                          0.907
  Number of patients receiving an inotropic agent                                                                                   
   Dobutamine, *n* (%)                                       9 (18.8)                          0 (0)                                0.190
   Dobutamine dose (mean ± SD), μg∙kg^−1^∙min^−1^            2.99 ± 2.56                                                            
   Epinephrine, *n* (%)                                      33 (68.8)                         21 (87.5)                            0.317
   Epinephrine dose (mean ± SD), μg∙kg^−1^∙min^−1^           0.11 ± 0.09                       0.44 ± 0.84                          0.207
   Milrinone, *n* (%)                                        21 (43.8)                         15 (62.5)                            0.386
   Milrinone dose (mean ± SD), μg∙kg^−1^∙min^−1^             0.40 ± 0.23                       0.32 ± 0.16                          0.524
  Lactate clearance, %                                       10.2 ± 31.5                       8.6 ± 18.2                           0.897
  Length of ICU stay, days                                   9.8 ± 6.3                         7.0 ± 3.8                            0.263
  Length of hospital stay, days                              42.8 ± 21.2                       42.8 ± 21.8                          0.995
  Mortality at day 28, %                                     12.5                              25.0                                 0.439

APACHE II: Acute physiological and chronic health evaluation II score; NYHA: New York Heart Association; CPB: Cardiopulmonary bypass; MAP: Mean arterial pressure; IQR: Interquartile range; ICU: Intensive Care Unit; SD: Standard deviation; VO~2~: Oxygen consumption.

At baseline, there were significant differences in P(v−a)CO~2~/C(a−v)O~2~ ratio and VO~2~ between the groups (2.2 ± 1.2 vs. 1.2 ± 0.4 mmHg/ml, *P* = 0.030 and 88.6 ± 28.5 vs. 130.3 ± 32.4 ml·min^−1^·m^−2^, *P* = 0.004, respectively); however, there were no significant differences in hemodynamic (such as central venous pressure \[CVP\], *CI*, GEDVI, SVRI and extravascular lung water index), global metabolic (such as DO~2~ and oxygen extraction ratio \[ERO~2~\]) or tissue perfusion parameters \[such as ScvO~2~, P(v−a)CO~2~, serum lactate and AGcorrected; [Table 3](#T3){ref-type="table"}\]. After intervention, there was a significant difference in ScvO~2~ between the groups (73.5% ± 6.4% vs. 79.2% ± 5.7%, *P* = 0.043), but not in any of the other hemodynamic, global metabolic or tissue perfusion variables \[[Table 3](#T3){ref-type="table"}\].

###### 

Hemodynamic and metabolic variables of the VO~2~ increase and VO~2~ no-increase groups

  Variables                                           VO~2~ increase group (*n* = 48)   VO~2~ no-increase group (*n* = 24)                      
  --------------------------------------------------- --------------------------------- ------------------------------------ ------------------ ----------------
  CVP (mean ± SD), mmHg                               9.5 ± 3.3^‡^                      12.1 ± 3.5                           9.3 ± 2.0^§^       11.4 ± 3.7
  GEDVI (mean ± SD), ml/m^2^                          664.1 ± 190.9                     686.5 ± 167.0                        672.5 ± 329.4      722.3 ± 333.7
  CI (mean ± SD), L∙min^−1^∙m^−2^                     3.0 ± 0.8^‡^                      3.7 ± 1.0                            3.2 ± 0.7^§^       3.9 ± 0.6
  SVRI (mean ± SD), dyn∙s^-1^∙cm^-5^∙m^-2^            2106.7 ± 954.1^‡^                 1565.9 ± 572.3                       2106.0 ± 711.2     1648.9 ± 594.0
  EVLWI (mean ± SD), ml/kg                            7.7 ± 2.5                         7.3 ± 2.4                            9.1 ± 5.5          10.1 ± 6.1
  DO~2~ (mean ± SD), ml∙min^−1^∙m^−2^                 408.5 ± 124.9^‡^                  499.4 ± 151.9                        497.8 ± 154.4^§^   594.9 ± 162.4
  VO~2~ (mean ± SD), ml∙min^−1^∙m^−2^                 88.6 ± 28.5\*^‡^                  129.3 ± 51.9                         130.3 ± 32.4       118.4 ± 37.9
  ERO~2~, %                                           22.7 ± 7.7^‡^                     26.0 ± 7.2                           28.3 ± 11.7        20.2 ± 5.3
  ScvO~2~, %                                          76.3 ± 6.7                        73.5 ± 6.4^†^                        73.4 ± 7.4^§^      79.2 ± 5.7
  Lactate (mean ± SD), mmol/L                         5.4 ± 3.1                         4.9 ± 3.5                            5.9 ± 3.3          5.5 ± 3.1
  P(v-a)CO~2~ (mean ± SD), mmHg                       6.2 ± 2.5                         4.3 ± 2.9                            4.9 ± 2.2          3.2 ± 2.6
  P(v-a)CO~2~/C(a-v)O~2~ ratio (mean ± SD), mmHg/ml   2.2 ± 1.2\*^‡^                    1.2 ± 0.8                            1.2 ± 0.4          1.1 ± 0.8
  AGcorrected (mean ± SD), mmol/L                     18.1 ± 5.1                        18.2 ± 4.9                           20.2 ± 3.0         19.0 ± 4.6

\**P* \< 0.05 for the VO~2~ increase group versus the VO~2~ no-increase group at baseline; ^†^*P* \< 0.05 for VO~2~ increase group versus VO~2~ no-increase group after intervention; ^‡^*P* \< 0.05 for the difference between baseline and intervention in the VO~2~ increase group; ^§^*P* \< 0.05 for the difference between baseline and intervention in the VO~2~ no-increase group. CVP: Central venous pressure; GEDVI: Global end diastolic volume index; CI: Cardiac index; SVRI: Systemic vascular resistance index; EVLWI: Extravascular lung water index; DO~2~: Oxygen delivery; VO~2~: Oxygen consumption; ERO~2~: Oxygen extraction ratio; ScvO~2~: Central venous oxygen saturation; P(v−a)CO~2~: Veno-arterial carbon dioxide difference; AGcorrected: Corrected anion gap; SD: Standard deviation; C(a-v)O~2~: Arterial-venous oxygen difference.

In the VO~2~ increase group, DO~2~ increased by 23% ± 13% (*P* \< 0.001) and VO~2~ by 46% ± 38% (*P* \< 0.001). The intervention to increase DO~2~ by \>10% significantly altered CVP (9.5 ± 3.3 vs. 12.1 ± 3.5 mmHg, *P* \< 0.001), *CI* (3.0 ± 0.8 vs. 3.7 ± 1.0 L·min^−1^·m^−2^, *P* \< 0.001), SVRI (2106.7 ± 954.1 vs. 1565.9 ± 572.3 dyn·s^-1^·cm^-5^·m^-2^, *P* = 0.002), ERO~2~ (22.7% ± 7.7% vs. 26.0% ± 7.2%, *P* = 0.047) and P(v−a)CO~2~/C(a−v)O~2~ ratio \[2.2 ± 1.2 vs. 1.2 ± 0.8 mmHg/ml, *P* = 0.013; [Table 3](#T3){ref-type="table"}\]. In the VO~2~ no-increase group, even though DO~2~ increased by 21% ± 11% (497.8 ± 154.4 vs. 594.9 ± 162.4 ml·min^−1^·m^−2^, *P* \< 0.001), VO~2~ fell by 7% ± 10% (130.3 ± 32.4 vs. 118.4 ± 37.9 ml·min^−1^·m^−2^, *P* = 0.086). Nonetheless, there were significant changes in CVP (9.3 ± 2.0 vs. 11.4 ± 3.7 mmHg, *P* = 0.018), *CI* (3.2 ± 0.7 vs. 3.9 ± 0.6 L·min^−1^·m^−2^, *P* \< 0.001) and ScvO~2~ (73.4% ± 7.4% vs. 79.2% ± 5.7%, *P* = 0.015) after intervention to improve DO~2~ \[[Table 3](#T3){ref-type="table"}\].

Baseline prediction of an oxygen consumption response to improved oxygen delivery {#sec2-6}
---------------------------------------------------------------------------------

A baseline P(v−a)CO~2~/C(a−v)O~2~ ratio ≥1.6 mmHg/ml predicted an improvement in VO~2~ when DO~2~ increased by \>10%, with a sensitivity of 68.8% and a specificity of 87.5%. The AUC was 0.77 ± 0.10 \[*P* = 0.032; [Figure 2](#F2){ref-type="fig"}\]. No other variable, including ScvO~2~, serum lactate or AGcorrected, significantly predicted a VO~2~ response \[[Table 3](#T3){ref-type="table"}\].

![Receiver operating characteristic (ROC) curve. ROC curve comparing the P(v−a)CO~2~/C(a−v)O~2~ ratio to an increase in oxygen consumption (VO~2~) brought about by increasing oxygen delivery (DO2) by \>10% in cardiac surgical patients. Area under the curve: 0.77 ± 0.10, *P* = 0.032, The cutoff of the P(v−a)CO~2~/C(a−v)O~2~ ratio value was 1.6 for predicting cardiac surgery patients in whom VO~2~ would increase when DO~2~ increased by \>10%, resulting in a sensitivity of 68.8% and a specificity of 87.5%.](CMJ-128-1306-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Our main finding was that the P(v−a)CO~2~/C(a−v)O~2~ ratio was a reliable marker of global anaerobic metabolism in cardiac surgery patients and predicts whether improved DO~2~ will result in an increase in VO~2~. This is particularly helpful in guiding the management of patients after cardiac surgery, when hyperlactatemia might not always represent anaerobic metabolism, and a normal ScvO~2~ may fail to reflect persistent tissue hypoxia.\[[@ref6]\] However, care must be exercised when seeking to elevate CO to improve DO~2~ in patients who have undergone cardiac surgery. The P(v−a)CO~2~/C(a−v)O~2~ ratio allows patients likely to respond to intervention to be treated appropriately without exposing those who will not to unnecessary risk. At baseline in postoperative cardiac surgery patients, a P(v−a)CO~2~/C(a−v)O~2~ ratio ≥1.6 mmHg/ml predicted a positive VO~2~ response when DO~2~ was increased by \>10%, with a sensitivity of 68.8% and a specificity of 87.5%. This finding is consistent with another recent study that found that a cut-off of 1.8 mmHg/ml had a reasonable sensitivity and specificity to predict VO~2~ response.\[[@ref7]\]

Physiological relevance of the P(v−a)CO~2~/C(a−v)O~2~ ratio {#sec2-7}
-----------------------------------------------------------

The P(v−a)CO~2~/C(a−v)O~2~ ratio positively correlates with the respiratory quotient (RQ). According to the Fick equation, VO~2~ is the product of CO and arteriovenous O~2~ content difference (C(a−v)O~2~). Carbon dioxide production (VCO~2~) is equal to the product of CO and veno-arterial CO~2~ content difference. Under most normal physiological circumstances, CO~2~ tension is linearly related to CO~2~ content, so an increase in the RQ should be reflected by an increase in the P(v−a)CO~2~/C(a−v)O~2~ ratio.\[[@ref11]\]

During tissue hypoxia, the reduction in global O~2~ consumption is accompanied by diminished aerobic but increased anaerobic CO~2~ production, with excess protons buffered mostly by bicarbonate ions.\[[@ref12]\] Thus, total VCO~2~ should be reduced less than VO~2~, hence, global anaerobic metabolism is reflected by increases in the RQ (VCO~2~/VO~2~) and P(v−a)CO~2~/C(a−v)O~2~ ratio.

Oxygen supply, demand and the P(v−a)CO~2~/C(a−v)O~2~ ratio {#sec2-8}
----------------------------------------------------------

At baseline, we found that P(v−a)CO~2~/C(a−v)O~2~ ratio was higher in the VO~2~ increase group and predicted a response to resuscitation when ScvO~2~ was normal, and serum lactate concentration was raised. Under these circumstances, hyperlactatemia equates with hypoxia. Friedman *et al*.\[[@ref8]\] reported that interventions to increase DO~2~ were justified when there was a VO~2~ response, and the use of the P(v−a)CO~2~/C(a−v)O~2~ ratio is underpinned by the same pathophysiological concept. Outcomes are very poor in patients with an oxygen deficit whose VO~2~ fails to respond to increased DO~2~.\[[@ref13]\] After cardiac surgery, the postoperative course is characterized by increases in cellular oxygen demand as a consequence of rising body temperature,\[[@ref14]\] emergence from anesthesia, and the resumption of spontaneous ventilation.\[[@ref15]\] Shivering, pain, and anxiety may further increase oxygen demand.\[[@ref16]\] In complex situations, plotting VO~2~/DO~2~ over time during a DO~2~ challenge allows the critical DO~2~ to be identified. This ensures that VO~2~ needs are met, a crucial objective even if DO~2~ and VO~2~ are estimated intuitively rather than measured directly. As DO~2~ increases beyond the critical point, VO~2~ may continue to rise slowly, rather than plateau. When oxygen requirements are excessive, DO~2~ becomes uncoupled from metabolic activity;\[[@ref17]\] as CO improves during a DO~2~ challenge, the VO~2~ of the muscles and viscera increase in direct proportion to blood flow.\[[@ref18][@ref19][@ref20]\] Furthermore, additional oxygen is taken up by nonmitochondrial oxidase systems as dysoxia resolves.\[[@ref21]\] It is therefore clinically important to be able to detect a VO~2~ response to a DO~2~ challenge, especially when the extent of oxygen deficit is unclear.

P(v−a)CO~2~/C(a−v)O~2~ ratio is superior to lactate and lactate clearance rate {#sec2-9}
------------------------------------------------------------------------------

Hyperlactatemia on admission to ICU after cardiac surgery was found to predict mortality in some single-center studies,\[[@ref22][@ref23]\] but not in larger studies.\[[@ref24][@ref25]\] Early after CPB, hyperlactatemia may reflect intraoperative factors rather than anaerobic metabolism, a concept supported by our findings. In our study, there were no significant differences in serum lactate concentrations between the groups at baseline, or before and after the intervention.

Hyperlactatemia may not be directly caused by tissue dysoxia. There is a delay of 30--60 min between myocardial reperfusion and normalization of lactate concentration measured in the coronary sinus, suggesting that anaerobic metabolism continues within the myocardium for some time after ischemia.\[[@ref26]\] Restoration of blood flow in animal and human models of circulatory failure results in lactate "washout" from regional tissues, especially from the coronary and renal circulations.\[[@ref1]\] Pulmonary lactate levels rise significantly after surgical trauma and CPB, and may contribute significantly to circulating lactate levels up to 6 h postoperatively.\[[@ref27]\] It has been hypothesized that lactate is used as a source of energy during physiological stress.\[[@ref6]\] When lactate remains high despite evidence that a VO~2~ plateau has been reached, there is no evidence that increasing DO~2~ further is beneficial,\[[@ref13]\] and indeed could be harmful in patients with impaired cardiac function. We observed a trend that serum lactate concentration fell after intervention, even in the group that did not mount a VO~2~ response, although the differences were not statistically significant. This could be explained by lactate "washout" or other factors. The kinetics of lactate clearance depends fundamentally on hepatic clearance, which appears to be preserved even during cardiogenic shock.\[[@ref28]\]

Early recognition of shock is critical, as it responds better to intervention in the early stages,\[[@ref29]\] and there is some evidence that rapidly achieving an adequate total body VO~2~ is a prerequisite of successful resuscitation. Delaying resuscitation causes macro- and microcirculatory failure and ultimately cell necrosis, which cannot be corrected by resuscitation. In shock, the oxygen deficit is only a "snapshot" calculated as the difference between baseline "normal" VO~2~ and the VO~2~ measured at a particular time; however, oxygen debt accumulates over time. The P(v−a)CO~2~/C(a−v)O~2~ ratio can be measured as a "snapshot," whereas measuring lactate clearance rate takes time, during which patients may be exposed to prolonged periods of tissue hypoperfusion.

P(v−a)CO~2~/C(a−v)O~2~ ratio is superior to central venous oxygen saturation {#sec2-10}
----------------------------------------------------------------------------

An ScvO~2~ \<60.8% is considered unsatisfactory after cardiac surgery and can be found in approximately 13% of patients. In contrast, supranormal levels \>77.4% occurs in approximately one-third of patients, and appears to be a warning sign of impaired tissue oxygenation and is associated with higher mortality.\[[@ref9]\] Patients with low ScvO~2~ and hyperlactatemia clearly require resuscitation, so we focused on patients with ScvO~2~ \>61%, where the situation is less clear. We did not, however, distinguish between patients with normal and supranormal ScvO~2~ as the boundaries between the two are less well defined.

Assuming that "supranormal" ScvO~2~ indicates impaired tissue oxygenation, there are three mechanisms that are likely responsible for the co-existence of normal or supranormal ScvO~2~ and hyperlactatemia after cardiac surgery: CPB or off-pump surgery with concomitant mitochondrial dysfunction; therapeutic interventions to increase DO~2~, most notably β-mimetics;\[[@ref4]\] and macrocirculatory failure combined with microcirculatory or mitochondrial failure. In health, VO~2~ is determined by the metabolic needs of the tissues and when DO~2~ increases VO~2~ remains relatively constant as the tissues adapt their ERO~2~ accordingly, known as oxygen supply independency. In shock, however, mitochondrial dysfunction or microvascular shunting may result in persistent anaerobic metabolism and static VO~2~ even as DO~2~ improves with resuscitation. Oxygen extraction and SvO~2~ (or ScvO~2~) are linked by a simple equation: ScvO~2~ = 1 − ERO~2~, which can be rewritten as ScvO~2~ = 1 − VO~2~/DO~2~ if it is assumed that SaO~2~ = 1. Thus, if DO~2~ is altered in the face of a relatively constant VO~2~, ScvO~2~ will increase, and ERO~2~ will fall. We found that there was a significant rise in ScvO~2~ in the VO~2~ no-increase group after intervention, but our study was unable to distinguish between patients with mitochondrial dysfunction or microcirculatory shunt and those with oxygen supply independency. Even so, further macrocirculatory resuscitation is not warranted in either case and a single baseline measurement of P(v−a)CO~2~/C(a−v)O~2~ ratio appears to be superior to ScvO~2~ in helping to identify patients likely to respond to intervention.

P(v−a)CO~2~/C(a−v)O~2~ ratio is superior to P(v−a)CO~2~ {#sec2-11}
-------------------------------------------------------

Veno-arterial PCO~2~ difference (P(v-a)CO~2~) has been proposed to be a marker of tissue hypoxia, and is also often used to guide resuscitation.\[[@ref30]\] However, it is not clear whether it reliably identifies VO~2~ responders. Van der Linden *et al*. found a significant correlation between blood lactate levels and P(v−a)CO~2~ in an animal model of acute hemorrhage,\[[@ref31]\] and progressive increases in P(v−a)CO~2~ have been observed during the VO~2~/DO~2~ dependent period as blood flow falls.\[[@ref32]\]

Hypoperfusion can result in a widening of P(v−a)CO~2~ even if no additional CO~2~ production occurs, known as the CO~2~-stagnation phenomenon. P(v−a)CO~2~ could, therefore, be considered to be an indicator of adequate venous blood flow to remove CO~2~ produced in the peripheries.\[[@ref33]\] In the isolated dog limb model of hypoxia, Vallet *et al*. found that P(v−a)CO~2~ was increased in ischemic hypoxia but not hypoxic hypoxia, suggesting that P(v−a)CO~2~ has poor sensitivity for detecting tissue hypoxia.\[[@ref34]\] P(v-a)CO~2~ = *k* × VCO~2~/CO, where *k* is assumed to be constant. VCO~2~ = RQ × VO~2~, CO = DO~2~/SaO~2~ × 1.34 × Hb. Comprehensive the above three equations, P(v−a)CO~2~ = RQ × ERO~2~ × SaO~2~ × Hb × *k*. If arterial oxygen saturation (SaO~2~) and Hb remain constant, P(v-a)CO~2~ is influenced by RQ and ERO~2~. A high ERO~2~ (and hence low ScvO~2~) is associated with increased mortality in the presence of high serum lactate concentration.\[[@ref6]\]

Although high ERO~2~ increases the numerical value of P(v−a)CO~2~, it does not reliably reflect anaerobic metabolism as there is significant individual variation in the anaerobic threshold. We found trends to suggest that P(v−a)CO~2~ was higher in the VO~2~ increase group than the VO~2~ no-increase group, and in the VO~2~ increase group before and after intervention, but the differences were not statistically significant.

P(v−a)CO~2~/C(a−v)O~2~ ratio is superior to corrected anion gap {#sec2-12}
---------------------------------------------------------------

The corrected and strong ion gaps have been advocated as surrogate markers of global anaerobic metabolism, and deficits in DO~2~ and cellular perfusion in cardiac critical care\[[@ref35]\] and AG has been used as a therapeutic target in research.\[[@ref36]\] Although the link between metabolic acidosis and tissue hypoperfusion is well-established, we found no relationship between AGcorrected and anaerobic metabolism as above.

Limitations {#sec2-13}
-----------

Our study has several limitations. First, myocardial ischemia and reperfusion injury and the effects of anesthetic drugs may limit tissue oxygen use and the CO response to DO~2~ challenge.\[[@ref37]\] In addition, resuscitation was not guided by the protocol but left to the discretion of the attending physician and thus ours is an observational study, albeit an observation of routine clinical practice. Second, only a small proportion of patients met our inclusion criteria, so our findings cannot be generalized to those in whom DO~2~ did not respond to intervention or those with arrhythmia. A larger multi-center study will be needed to confirm our findings and determine more accurate ratio cutoff values. Third, hyperthermia, acute respiratory failure, and pain increase VO~2~ needs sharply. Antipyretic drugs, sedation, and mechanical ventilation\[[@ref38]\] can reduce VO~2~ by up to 50%, so can have the same effect as doubling CO or ERO~2~. When seeking to improve DO~2~, it is also important to reduce VO~2~, but we did not examine the benefits of interventions that decrease VO~2~, instead we sought to identify patients able to mount a DO~2~ response to resuscitation. After cardiac surgery hyperlactatemia does not always reflect anaerobic metabolism, and a normal ScvO~2~ does not indicate that resuscitation has been adequate. We found that the P(v−a)CO~2~/C(a−v)O~2~ ratio appears to be a reliable marker of global anaerobic metabolism and predicts response to DO~2~ challenge, suggesting that it may be a useful resuscitation target.

In conclusion, P(v−a)CO~2~/C(a−v)O~2~ ratio appears to be a reliable marker of global anaerobic metabolism and predicts response to DO~2~ challenge. Thus, patients likely to benefit from resuscitation can be identified promptly, and those in whom a VO~2~ response is unlikely can be spared the unnecessary risks associated with fluid overload and positive inotropic drugs. The P(v−a)CO~2~/C(a−v)O~2~ ratio may, therefore, be a useful resuscitation target.
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